At Hope4Cancer Institute we have the technology and know-how to extract, from urine, the proteins that are produced by the cancer cells and develop a vaccine "Autologous Antigen Receptor Specific Oncogenic Target Acquisition" (AARSOTA). This vaccine is administered intramuscularly at specific intervals to promote an antigen-antibody response and provide immunological information to the antibodies. The immunological response enhances specific cancer fighting ability by the body's defense system.
Tumor markers are measurable biochemicals that are associated with a malignancy. They are either produced by tumor cells (tumor-derived) or by the body in response to tumor cells (tumor-associated). They are typically substances that are released into the circulation and thus measured in the blood. There are a few exceptions to this, such as tissue-bound receptors that must be measured in a biopsy from the solid tumor or proteins that are secreted into the urine.
Though tumor markers are rarely specific enough to be used alone to diagnose cancer, they do have a number of clinical uses. They can be used to stage cancer, to indicate a prognosis, to monitor treatment, or in follow-up to watch for cancer recurrence. Changes in some tumor markers have been sensitive enough to be used as targets in clinical trials. When used for diagnosis, tumor markers are used in conjunction with other clinical parameters such as biopsy and radiological findings. Although there are a multitude of tumor markers, very few of them have found their way into clinical practice because of their lack of specificity. However, some of these non-specific markers have found a place in monitoring cancer treatment rather than in diagnosis.
As tumor cells grow and multiply, some of their substances can increase and leak into the bloodstream or other fluids. Depending upon the tumor marker, it can be measured in blood, urine, stool or tissue. Some widely used tumor markers include: AFP, beta-HCG, CA 15-3, CA 19-9, CA 27.29, CA 125, CEA, and PSA. Some tumor markers are associated with many types of cancer; others, with as few as one. Some tumor markers are always elevated in specific cancers; most are less predictable. However, no tumor marker is specific for cancer and most are found in low levels in healthy persons, or can be associated with non-neoplastic diseases as well as cancer. Also, no tumor marker test is free of false negatives or false positives.
Once cancer is diagnosed, tumor marker levels sometimes help to determine the extent of cancer. Higher levels can indicate more advanced cancer and a worse prognosis in some cases. The patient and their physician may use this information to choose between more or less aggressive treatments.
Monitoring cancer treatment is the most common use of tumor markers. As cancer is reduced, levels often decrease. Stable or increasing levels often indicate that the cancer is not responding to treatment. The choice of tumor marker to use for monitoring is important. Only a marker elevated before treatment should be used to monitor a person during or after treatment. Timing of the tests is also important. Each tumor marker has a unique life span in the blood. To monitor a treatment's success, enough time must have passed for the initial marker to be cleared from the blood. Tests done too soon may be falsely elevated because the marker produced by the untreated cancer is still present.
Watching for cancer recurrence after treatment is another reason for tumor marker testing. Periodic testing can sometimes detect a recurrence often months earlier than could an ultrasound, x ray, or physical examination.
There is not a good consensus in the medical community about the value of most tumor markers. Because they lack specificity and accuracy, their use is limited. False positives can cause emotional distress and fear. It is not yet determined if there is a savings of life or money with testing. Currently, much controversy surrounds the issue of mass screening for cancer using tumor markers.
At Hope4Cancer Institute we have the technology and know-how to extract, from urine, the proteins that are produced by the cancer cells and develop a vaccine (AARSOTA). This vaccine is administered intramuscularly at specific intervals to promote an antigen-antibody response and provide immunological information to the antibodies. The immunological response enhances specific cancer fighting ability by the bodies defense system. Coupled with specialized transdermal peptides we have greatly enhanced the ability of the immune system, in immuno-compromised cancer patients, to boost its suppressive nature.
"Knowing the natural intelligence of your immune system is crucial in recovery from cancer", says Dr. Jimenez.